Search
Beijing Sinovac Sinoway Biotech Co., Ltd.'s adsorbed tetanus vaccine has garnered approval from the National Medical Products Administration. Leveraging nanometer-scale adjuvant technology and sophisticated purification processes, this vaccine boasts enhanced immunogenicity and safety. Phase III clinical trials have confirmed its superiority, with antibody levels surpassing those of the control vaccine, while maintaining an excellent safety profile.
Sinovac is actively expanding its footprint in the trauma care sector, not only advancing the R&D of this vaccine but also undertaking clinical studies on anti-tetanus toxin monoclonal antibodies. Furthermore, the company is driving the launch of other innovative vaccines and monoclonal antibody products to address the diverse clinical needs of disease prevention and control.
-
C114 Communication Network -
Communication Home
